Berenberg Bank restated their buy rating on shares of ANGLE (LON:AGL – Get Rating) in a research report report published on Friday morning, Marketbeat.com reports. They currently have a GBX 231 ($2.83) target price on the stock.
ANGLE Stock Performance
Shares of ANGLE stock opened at GBX 71.50 ($0.88) on Friday. The company has a quick ratio of 7.54, a current ratio of 8.01 and a debt-to-equity ratio of 5.80. The stock has a market cap of £186.25 million and a price-to-earnings ratio of -10.67. The company’s fifty day moving average is GBX 97.06 and its 200 day moving average is GBX 99.57. ANGLE has a twelve month low of GBX 67 ($0.82) and a twelve month high of GBX 163.75 ($2.01).
In other news, insider Andrew D. Newland acquired 125,000 shares of the firm’s stock in a transaction on Tuesday, July 19th. The stock was purchased at an average price of GBX 80 ($0.98) per share, for a total transaction of £100,000 ($122,534.00).
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD multiplex analysis system for routine and focused multiplex analysis of DNA, RNA or protein biomarkers.
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for ANGLE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANGLE and related companies with MarketBeat.com's FREE daily email newsletter.